| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US7470433 | MYLAN SPECIALITY LP | Formulations for transdermal or transmucosal application |
Aug, 2021
(2 years ago) | |
| US7198801 | MYLAN SPECIALITY LP | Formulations for transdermal or transmucosal application |
Jun, 2022
(1 year, 10 months ago) | |
Elestrin is owned by Mylan Speciality Lp.
Elestrin contains Estradiol.
Elestrin has a total of 2 drug patents out of which 2 drug patents have expired.
Expired drug patents of Elestrin are:
- US7470433
- US7198801
Elestrin was authorised for market use on 15 December, 2006.
Elestrin is available in gel, metered;transdermal dosage forms.
The generics of Elestrin are possible to be released after 25 June, 2022.
Drugs and Companies using ESTRADIOL ingredient
Market Authorisation Date: 15 December, 2006
Treatment: NA
Dosage: GEL, METERED;TRANSDERMAL
More Information on Dosage
ELESTRIN family patents
